Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanologica AB ( (SE:NICA) ) has provided an announcement.
Nanologica AB’s 2026 Annual General Meeting approved the 2025 financial statements and decided that the accumulated loss of SEK 50.2 million will be carried forward, meaning no dividend will be paid for the year. The meeting also granted discharge from liability to the board and CEO, re-elected five directors, appointed two new members, confirmed Thomas Eldered as chairman, and kept board and committee fees unchanged.
Shareholders approved BDO Mälardalen AB as auditor with Niclas Nordström continuing in charge, and endorsed the board’s remuneration report for 2025. The AGM further amended the articles of association to lower the range for share capital, resolved to reduce share capital by about SEK 10.2 million to cover losses, and authorized the board to issue new shares, convertibles or warrants of up to 20% of existing share capital, with or without preferential rights, until the next AGM.
More about Nanologica AB
Nanologica AB is a Swedish life science group specializing in advanced solutions for developing, manufacturing and purifying pharmaceutical substances. Leveraging materials science, nanotechnology and chemical process development, the company offers contract development and manufacturing services, with particular strength in complex molecules and peptide-based drugs for conditions such as diabetes and obesity.
Average Trading Volume: 3,230,697
Technical Sentiment Signal: Sell
Current Market Cap: SEK213.7M
For a thorough assessment of NICA stock, go to TipRanks’ Stock Analysis page.